Modality
Multispecific
MOA
PARPi
Target
LAG-3
Pathway
Angiogenesis
CMLCTCL
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
~Jul 2021
→ ~Oct 2022
Phase 2
Jan 2023
→ Jul 2027
Phase 2Current
NCT05032670
359 pts·CTCL
2024-07→2027-07·Recruiting
NCT07379957
549 pts·CTCL
2023-01→2026-07·Recruiting
908 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-244mo awayPh3 Readout· CTCL
2027-07-051.3y awayPh3 Readout· CTCL
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Recruit…
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-07-24 · 4mo away
CTCL
Ph3 Readout
2027-07-05 · 1.3y away
CTCL
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05032670 | Phase 2/3 | CTCL | Recruiting | 359 | DAS28 |
| NCT07379957 | Phase 2/3 | CTCL | Recruiting | 549 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |